Societal value of generic medicines beyond cost-saving through reduced prices

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 15, Issue 4, 2015, Pages 701-711

  Dylst, Pieter ^a   Vulto, Arnold ^b   Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Access; Adherence; Generic medicines; Innovation; Value

Indexed keywords

ALENDRONIC ACID; AMLODIPINE; ANTIHYPERTENSIVE AGENT; CLOPIDOGREL; ESOMEPRAZOLE; FELODIPINE; FLUINDOSTATIN; GENERIC DRUG; LISINOPRIL; OMEPRAZOLE; PANTOPRAZOLE; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SIMVASTATIN; TEMOZOLOMIDE;

BUDGET; CASE STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DISEASES; DRUG COST; DRUG INDUSTRY; EXERCISE; HEALTH CARE ACCESS; HUMAN; HYPERTENSION; NETHERLANDS; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; REVIEW; SOCIAL ASPECT; SYSTEMATIC REVIEW; COMMERCIAL PHENOMENA; DRUG LEGISLATION; ECONOMICS; HEALTH CARE DELIVERY; HEALTH CARE POLICY; LEGISLATION AND JURISPRUDENCE; MEDICATION COMPLIANCE;

COMMERCE; COST SAVINGS; DRUG COSTS; DRUGS, GENERIC; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; LEGISLATION, DRUG; MEDICATION ADHERENCE; NETHERLANDS;

EID: 84945905378     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2015.1017565     Document Type: Review

References (66)

1. Simoens S, De Coster S. Sustaining generic medicines markets in Europe. 1-100. 2006. Leuven, Belgium, KU Leuven
2. European Commission. Directive 2004/27/EC of the European Parliament and of the Council of 31st March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Union L 136/34-57. 2004
3. Simoens S. International comparison of generic medicine prices. Curr Med Res Opin 2007; 23(11):2647-54
4. Simoens S, De Coster S. Sustaining generic medicines markets in Europe. J Gene Med 2006; 3(4):257-68
5. Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries - an overview. GaBi Journal 2012; 1(2):93-100
6. Godman B, Abuelkhair M, Vitry A., et al. Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach. GaBi Journal 2012; 1(2):69-83
7. van Woerkom M., Piepenbrink H, Godman B., et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res 2012; 1(6): 527-38
8. Godman B, Bennie M, Baumgärtel C, et al. Essential to increase the use of generics in Europe to maintain comprehensive health care. Farmeconomia: Health Economics and Therapeutic Pathways 2012; 13(3):5-20
9. Bennie M, Godman B, Bishop I., Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res 2012; 12(1):125-30
10. European Generic Medicines Association. 2011 Market Review. Brussels, Belgium; 2011; European Generic Medicines Association
11. Dylst P, Vulto A, Simoens S. Analysis of European policy towards generic medicines. GaBi Journal 2014; 3(1):34-5
12. Dylst P, Vulto A, Godman B., Simoens S. Generic medicines: solutions for a sustainable drug market? Appl Health Econ Health Policy 2013; 11(5):437-43
13. Gumbs P, Verschuren M, Souverein P., et al. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. Br J Clin Pharmacol 2007; 64(5):680-5
14. Anonymous. Dutch body counts off-patent savings. News@Genericsbulletin 2013
15. Anonymous. German savings exceed EUR2 billion. News@Genericsbulletin 2013
16. Wettermark B, Godman B, Andersson K., et al. Recent national and regional drug reforms in Sweden - Implication for pharmaceutical companies in Europe. Pharmacoeconomics 2008; 26:537-50
17. Ubeda A, Cardo E, Selles N., et al. Antidepressant utilization in primary care in a Spanish region. Impact of generic and reference-based pricing policy (2000-2004). Soc Psychiatry Psychiatr Epidemiol 2007; 42:181-8
18. World Health Organization Collaborating Centre for Drug Statistics and Methodology. DDD: definition and general consideration. 2012. Available from: www.whocc.no; Oslo, WHOCC
19. World Health Organization Collaborating Centre for Drug Statistics and Methodology. Use of ATC/DDD. 2012. Oslo, WHOCC
20. Godman B, Shrank W, Andersen M., et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implication. Expert Rev Pharmacoecon Outcomes Res 2010; 10(6):707-22
21. Sheppard A. Generic medicines: essential contributors to the long-term health of society. Sector sustainability challenges in Europe; 114 2010. London, UK; IMS
22. Bazargani Y, Ewen M, de Boer A, et al. Essential medicines are more available than other medicines around the globe. PLoS One 2014; 9(2):e87576
23. Opening keynote speech. 20th EGA Annual Conference; Madrid, Spain; 2014
24. Simoens S, Sinnaeve P. Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy. Cardiovascular Drugs Therapy 2013; 27: 49-60
25. Heart Protection Study Collaborative Group. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20536 individuals. The Lancet 2005; 365: 1779-85
26. Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet 2012; 380:581-90
27. Yurttutan S, Erdeve O, Oncel M.Y., et al. The relationship between trough drug concentrations and ductal closure in preterm infants treated with three-dose-oral ibuprofen. J Matern Fetal Neonatal Med 2013; 26(13):1306-10
28. Simoens S. Innovation throug generic medicines: is it time for a pan-European policy? J Generic Medicines 2008; 6(1):3-8
29. Bugeja V. Medicines: mere generic facts. Journal of the Malta College of Pharmacy Practice 2007; 13:42-4
30. Charles River Associates. Innovation in the pharmaceutical sector 2004. Brussels, Belgium; European Commission
31. Barei F, Le Pen C, Simoens S. The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation. GaBi Journal 2013; 2(1): 13-19
32. Briesacher B, Gurwitz J, Soumerai S. Patients at-risk for cost-related medication nonadherence: a literature review. J Gen Intern Med 2007; 22:864-71
33. Shah N, Hirsch A, Zacker C., et al. Predictors of first-fill adherence for patients with hypertension. Am J Hypertens 2009; 22(4):392-6
34. Neugut A, Milayna S, Wilde E.T., et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 2011; 2011(29):18-2534
35. Eaddy M, Cook C, O'Day K, et al. How patient cost-sharing trends affect adherence and outcomes. A literature review. P T 2011; 37(1):45-55
36. Maciejewski M, Farley J, Parker J., Wansink D. Copayment reductions generate greated medication adherence in targeted patients. Health Aff 2010; 29(11):2002-8
37. Lesen E, Andersson Sundell K, Carlsten A, et al Is the level of patient co-payment for medicines associated with refill adherence in Sweden? Eur J Public Health 2014; 24(1): 85-90
38. Ellis J, Erickson S, Stevenson J., et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. Should we target patients with the most to gain? J Gen Intern Med 2004; 19:638-45
39. Roblin D, Platt R, Goodman M., et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations. How much is too much? Med Care 2005; 43(10):951-9
40. Goldman D, Geoffrey J, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. J Am Med Assoc 2007; 298(1):61-9
41. Babazono A, Miyazaki M, Imatoh T., et al. Effects of the increase in co-payments from 20 to 30 percent on the compliance rate of patients with hypertension or diabetes mellitus in the employed health insurance system. Int J Technol Assess Health Care 2005; 21(2):228-33
42. Doshi J, Zhu J, Lee B., et al. Impact of a prescription copayment increase on lipid lowering medication adherence in veterans. Circulation 2009; 119(3):390-7
43. Goldman D, Joyce G, Escarce J., et al. Pharmacy benefits and the use of drugs by the chronically ill. J Am Med Association 2004; 291(19):2344-50
44. Simoens S, Sinnaeve P. Patient co-payment and adherence to statins: A review and case studies. Card Drugs Therapy 2014; 28(1): 99-109
45. Briesacher B, Andrade S, Fouayzi H., Chan A. Medication adherence and the use of generic drug therapies. Am J Manag Care 2009; 15(7):450-6
46. Shrank W, Hoang T, Ettner S., et al. The implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med 2006; 166: 332-7
47. Colombo G, Agabiti-Rosei E, Margonato A., et al. Off-patent generic medicines vs. off-patent brand medicines for six reference drugs: a retrospective claims data study from five local healthcare units in the Lombardy Region of Italy. PLoS One 2013; 8(12): e82990
48. van Wijk B., Klungel O, Heerdink E., de Boer A. Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother 2005; 40: 15-20
49. Hershman D, Tsui J, Meyer J., et al. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early stage breast cancer. 2013 San Antonio Breast Cancer Symposium; 2013
50. Bao Y, Ryan A, Shao H., et al. Generic initiation and antidepressant therapy adherence under Medicare Part D. Am J Manag Care 2013; 19(12):989-98
51. Vlahiotis A, Devine S, Eichholz J., Kautzner A. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans. J Manag Care Pharm 2011; 17(2):123-32
52. Bello S. Adherence and generic substitution among hypertensive patients in a specialist hospital, Nigeria. Global J Med Res 2012; 12:2
53. Kamerow D. The pros and cons of generic drugs. BMJ 2011; 343:d4584
54. Håkonsen H., Eilertsen M, Borge H., Toverud E-L. Generic substitution: an additional challenge for adherence in hypertensive patients? Curr Med Res Opin 2009; 25(10):2515-21
55. Håkonsen H., Toverud E-L. Special challenges for drug adherence following generic substitution in Pakistani immigrants living in Norway. Eur J Clin Pharmacol 2011; 67:193-201
56. Emery J, McKenzie A, Bulsara C., Holman D. Confusion caused by generic substitution [electronic response to Ferner et al]. Controversy over generic substitution. British Medical Journal. 2010. Available from: www.bmj.com/content/340/bmj.c2548.full/reply#bmj-el-237995
57. van Gelder T., Vulto A. [Het gaat fout met die steeds wisselende geneesmiddelen]. NRC Handelsblad 2014
58. Dylst P, Vulto A, Simoens S. Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharmacoecon Outcomes Res 2013; 13(1): 59-72
59. Greene J, Kesselheim A. Why do the same drugs look different? Pills, trade dress, and public health. N Engl J Med 2011; 365(1): 83-9
60. European Commission. Pharmaceutical Sector Inquiry: Final Report. 1-533. 2009. Brussels, Belgium; European Commission
61. Dylst P, Vulto A, Simoens S. Analysis of French generic medicines retail market: Why the use of generic medicines is limited. Expert Rev Pharmacoecon Outcomes Res 2014; 14(6):795-803; Accepted for publication
62. Autorite de la concurrence. The Autorite de la concurrence fines Sanofi-Aventis a total of e40.6 million for disparaging the generic versions of Plavix, one of the world's best selling medicines. Available from: www.autoritedelaconcurrence.fr/user/standard.php?id-rub=483&id-article=2091. 2013; Paris, France, Autorite de la concurrence
63. Baumgärtel C., Godman B, Malmström R, et al. What lessons can be learned from the launch of generic clopidogrel. GaBi Journal 2012; 1(2):58-68
64. GaBi Online. Generic makers to be penalized for huge price hikes. GaBi Online 09/01/2015. Available from: www.gabionline.net/Policies-Legislation/Genericsmakers-to-be-penalized-for-huge-price-hikes
65. Dylst P, Vulto A, Simoens S. Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainability. Expert Rev Pharmacoecon Outcomes Res 2014; 14(3):345-53
66. Dylst P, Simoens S. Does the market share of generic medicines influence the price level? A European analysis. Pharmacoeconomics 2011; 29(10):875-82